A Prescient Podcast on Visionary Planning in Biopharma
The cost of bringing a single new molecule to market has soared to nearly $6 billion, yet most assets never make it to approval. In an environment defined by uncertainty, complexity and escalating risk, the most successful biopharma leaders share one common trait: they define a clear, long-term vision early.
In our latest podcast series, our experts explore why setting a bold “North Star” in the earliest stages of asset development is no longer optional, but a strategic imperative. Through real-world examples from leading organizations, including Pfizer, AstraZeneca and Amgen, the conversation unpacks how visionary planning helps teams align faster, make better decisions and ultimately improve the odds of success across the asset lifecycle.
What You’ll Hear
- Why early-asset vision matters more than ever in a $6 billion+ per-asset reality
- How leading biopharma teams define and operationalize a strategic “North Star”
- Lessons from real-world case studies that show vision in action
- Frameworks for navigating uncertainty and long-range decision-making
- How early alignment across functions unlocks downstream value
Listen to the podcast to learn how early vision can shape long-term outcomes: Prescient Deep Dive Podcast | Podcast on Spotify
Want to go deeper? Download the related whitepaper for more details on frameworks, data and detailed case studies.
Download the whitepaper: https://prescienthg.com/set-your-north-star-a-strategic-imperative-for-early-asset-success/